Nasdaq

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Nasdaq

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...

A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention

Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings ...

Recursion Highlights Q1 2026 Results and Pipeline Progress

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.